S. Yamashita

发表

Mathematical Modeling of Planar Cell Polarity To

M. Matsuda, M. Nishizawa, K. Segawa, 2008 .

Abdominal fat: standardized technique for measurement at CT.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1999, Radiology.

Betacellulin and Amphiregulin Induce Upregulation of Cyclin D1 and DNA Synthesis Activity Through Differential Signaling Pathways in Vascular Smooth Muscle Cells

S. Yamashita, Y. Matsuzawa, In-kyu Lee, 2003, Circulation research.

Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats.

S. Yamashita, Y. Matsuzawa, Toshikazu Nakamura, 2002, Journal of hepatology.

Role of LCAT in HDL remodeling: investigation of LCAT deficiency states Published, JLR Papers in Press, December 20, 2006.

S. Yamashita, G. Franceschini, E. Schaefer, 2007, Journal of Lipid Research.

HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins.

S. Yamashita, Y. Sawa, A. Matsuyama, 2010, Journal of atherosclerosis and thrombosis.

Roles of plasma lipid transfer proteins in reverse cholesterol transport.

M Ishigami, S. Yamashita, Y. Matsuzawa, 2001, Frontiers in bioscience : a journal and virtual library.

Distal protection during primary coronary intervention can preserve the index of microcirculatory resistance in patients with acute anterior ST-segment elevation myocardial infarction.

S. Yamashita, Hirotaka Sawano, Tomoaki Natsukawa, 2011, Circulation journal : official journal of the Japanese Circulation Society.

High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil.

S. Yamashita, Hirotaka Sawano, Y. Hayashi, 2010, Circulation journal : official journal of the Japanese Circulation Society.

Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.

S. Yamashita, I. Komuro, M. Nishida, 2010, Journal of atherosclerosis and thrombosis.

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

T Nakamura, M. Matsuda, S. Kihara, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions.

S. Yamashita, M. Nishida, T. Ohama, 2010, Journal of atherosclerosis and thrombosis.

Insulin Resistance and Body Fat Distribution: Contribution of visceral fat accumulation to the development of insulin resistance and atherosclerosis

S. Yamashita, Y. Matsuzawa, K. Kotani, 1996, Diabetes Care.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

J. Car, H. Schunkert, S. Yamashita, 2018, Atherosclerosis.

Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study".

S. Yamashita, Z. Ademi, G. Watts, 2019, Journal of clinical lipidology.

Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase.

S. Kihara, S. Yamashita, Y. Matsuzawa, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Other high-risk conditions.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017

S. Yamashita, T. Okamura, H. Arai, 2018, Journal of atherosclerosis and thrombosis.

Special Report Guidelines for the Management of Familial Hypercholesterolemia

S. Yamashita, T. Okamura, H. Arai, 2012 .

Role of membrane-anchored heparin-binding epidermal growth factor-like growth factor and CD9 on macrophages.

S. Kihara, S. Yamashita, T. Funahashi, 1997, The Biochemical journal.

Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia

S. Kihara, S. Yamashita, T. Funahashi, 1997, International Journal of Obesity.

Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

S. Yamashita, Y. Matsuzawa, T. Arai, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Juxtacrine Growth Mechanism on Smooth Muscle Cell Proliferation Like Growth Factor, in Human Atherosclerotic Plaques : Possible Involvement of − Factor Localization of CD9, an Enhancer Protein for Proheparin-Binding Epidermal Growth

S. Yamashita, R. Tamura, N. Ouchi, 2000 .

Localization of CD 9 , an Enhancer Protein for Proheparin-Binding Epidermal Growth Factor – Like Growth Factor , in Human Atherosclerotic Plaques Possible Involvement of Juxtacrine Growth Mechanism on Smooth Muscle Cell Proliferation

S. Kihara, S. Yamashita, Y. Matsuzawa, 2000 .

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Management of type IIb dyslipidemia.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

B. Yan, S. Yamashita, B. Yan, 2020, Journal of atherosclerosis and thrombosis.

Characterization of low-density lipoproteins from patients with recessive X-linked ichthyosis.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1988, Atherosclerosis.

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

S. Yamashita, H. Arai, E. Araki, 2018, Journal of diabetes investigation.

Enhanced expression of hepatic acyl‐coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1998, Hepatology.

Two decades of annual medical examinations in Japanese obese children: Do obese children grow into obese adults?

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1997, International Journal of Obesity.

Fasting plasma insulin level is an important risk factor for the development of complications in Japanese obese children--results from a cross-sectional and a longitudinal study.

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1995, Metabolism: clinical and experimental.

Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia.

S. Yamashita, Y. Matsuzawa, T. Maruyama, 2000, Atherosclerosis.

Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

P. Libby, S. Yamashita, R. Santos, 2019, Diabetes & metabolic syndrome.

Postprandial Hyperlipidemia and Remnant Lipoproteins

S. Yamashita, D. Masuda, Daisaku Masuda, 2017, Journal of atherosclerosis and thrombosis.

Recent Advances in Analytical Methods on Lipoprotein Subclasses: Calculation of Particle Numbers from Lipid Levels by Gel Permeation HPLC Using "Spherical Particle Model".

S. Yamashita, M. Okazaki, 2016, Journal of oleo science.

Cerebrovascular diseases.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

S. Yamashita, Y. Matsuzawa, D. Masuda, 2020, Current Atherosclerosis Reports.

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

S. Yamashita, Y. Matsuzawa, D. Masuda, 2019, Journal of atherosclerosis and thrombosis.

Where are we with probucol: a new life for an old drug?

S. Yamashita, Y. Matsuzawa, 2009, Atherosclerosis.

Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.

S. Yamashita, Yoshiya Tanaka, D. Masuda, 2016, Endocrine journal.

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

S. Yamashita, H. Arai, E. Araki, 2019, International journal of molecular sciences.

High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells.

S. Kihara, S. Yamashita, Y. Matsuzawa, 1998, Atherosclerosis.

Very High Levels of High-Density Lipoprotein Cholesterol and Cardiovascular Events in Japanese Population.

S. Yamashita, D. Masuda, Daisaku Masuda, 2016, Journal of atherosclerosis and thrombosis.

Cell surface-expressed moesin-like HDL/apoA-I binding protein promotes cholesterol efflux from human macrophages Published, JLR Papers in Press, October 26, 2005.

S. Yamashita, N. Sakai, K. Hirano, 2006, Journal of Lipid Research.

Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia.

S. Yamashita, Y. Matsuzawa, T. Arai, 2003, Atherosclerosis.

Cell-Surface Expressed Moesin-Like HDL/Apo A-I Binding Protein Is Involved in Cholesterol Efflux from Human Monocyte-derived Macrophages

S. Yamashita, Y. Matsuzawa, T. Sugimoto, 2002 .

Identification of a GPI-anchored type HDL-binding protein on human macrophages.

S. Kihara, S. Yamashita, Y. Matsuzawa, 2000, Biochemical and biophysical research communications.

Molecular disorders of cholesteryl ester transfer protein.

S. Yamashita, Y. Matsuzawa, T. Arai, 1996, Journal of atherosclerosis and thrombosis.

Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: Relationship to abnormalities in high‐density lipoprotein

S. Yamashita, Y. Matsuzawa, S. Kawata, 1993, Hepatology.

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography

S. Yamashita, A. Hirayama, A. Kiyosue, 2020, Journal of atherosclerosis and thrombosis.

Human scavenger receptor class B type I is expressed with cell-specific fashion in both initial and terminal site of reverse cholesterol transport.

S. Yamashita, M. Nishida, N. Sakai, 2005, Atherosclerosis.

Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease.

S. Yamashita, I. Komuro, M. Nishida, 2012, Journal of atherosclerosis and thrombosis.

Low-density lipoproteins in hyperalphalipoproteinemic heavy alcohol drinkers have reduced affinity for the low-density lipoprotein receptor.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1992, Clinical biochemistry.

Committee Report 16 Women

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Polydisperse low-density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction of cholesteryl ester transfer protein activity.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1992, Metabolism: clinical and experimental.

Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency.

S. Yamashita, Y. Matsuzawa, N. Sakai, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)

S. Yamashita, A. Saremi, P. Reaven, 2013, Diabetes Care.

Fasting remnant lipoproteins can predict postprandial hyperlipidemia

S. Yamashita, S. Kawano, Y. Fujioka, 2012, Lipids in Health and Disease.

Rapid Communication Clinical and Biochemical Characteristics of Familial Hyperalphalipoproteinemia Associated with Complete Deficiency of Cholesteryl Ester Transfer Activity*

S. Yamashita, N. Sakai, S. Tarui, 2011 .

Clinical and Biochemical Characteristics of Familial Hyperaiphalipoproteinemia Associated with Complete Deficiency of Cholesteryl Ester Transfer Activity

S. Yamashita, Y. Matsuzawa, N. Sakai, 1990 .

Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-κB pathway.

S. Yamashita, H. Yoshikawa, Satoru Otsuru, 2018, Biochemical and biophysical research communications.

Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.

S. Yamashita, H. Arai, E. Araki, 2018, Journal of clinical lipidology.

Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.

S. Yamashita, I. Komuro, M. Nishida, 2010, Journal of atherosclerosis and thrombosis.

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

S. Yamashita, H. Arai, E. Araki, 2019, International journal of molecular sciences.

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999.

S. Kihara, S. Yamashita, T. Funahashi, 2012, Biochemical and biophysical research communications.

Diagnosis and management of type I and type V hyperlipoproteinemia.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Association of Kidney Function with Serum Levels of Cholesterol Absorption and Synthesis Markers: The CACHE Study CKD Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2022, Journal of atherosclerosis and thrombosis.

Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria.

S. Yamashita, Y. Sakata, D. Masuda, 2014, Journal of atherosclerosis and thrombosis.

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.

J. Car, H. Schunkert, S. Yamashita, 2016, Atherosclerosis. Supplements.

Guidelines for the management of familial hypercholesterolemia.

S. Yamashita, T. Okamura, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty

S. Yamashita, Y. Matsuzawa, I. Shimomura, 1996, Nature Medicine.

Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin

M. Matsuda, M. Nishizawa, K. Segawa, 2005, Science.

Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet.

S. Yamashita, Y. Matsuzawa, S. Tarui, 1986, International journal of obesity.

Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction

S. Yamashita, M. Nishino, Hiroyasu Kato, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism.

S. Yamashita, G. Watts, T. Ng, 2005, Clinical chemistry.

Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism.

S. Yamashita, G. Watts, T. Ng, 2005, Clinical chemistry.

Committee Report 14 Cerebrovascular Diseases

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Minocycline for the treatment of Takayasu arteritis.

S. Yamashita, M. Ishigami, N. Sakai, 2005, Annals of internal medicine.

Matrix metalloproteinases as novel disease markers in Takayasu arteritis.

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2004, Circulation.

Matrix Metalloproteinases as Novel Disease Markers in Takayasu Arteritis

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2003 .

Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target.

S. Yamashita, K. Shimamoto, Y. Kiyohara, 2008, Journal of atherosclerosis and thrombosis.

A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins.

S. Yamashita, P. Kussie, X. Jiang, 1993, The Journal of clinical investigation.

Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect.

S. Yamashita, Y. Matsuzawa, D. Sprecher, 1990, Biochemical and biophysical research communications.

Pathophysiology of human genetic CD36 deficiency.

S. Yamashita, Y. Matsuzawa, K. Hirano, 2003, Trends in cardiovascular medicine.

Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1988, The American journal of cardiology.

Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages.

Masaki Tanaka, S. Yamashita, I. Shimomura, 2007, Journal of lipid research.

Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-α secretion in Abca1-deficient macrophagess⃞ Published, JLR Papers in Press, November 7, 2006.

Masaki Tanaka, S. Yamashita, I. Shimomura, 2007, Journal of Lipid Research.

Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey

P. Libby, S. Yamashita, Y. Matsuzawa, 2020, Lipids in Health and Disease.

Reduced adhesion of monocyte-derived macrophages from CD36-deficient patients to type I collagen.

K. Matsumoto, S. Yamashita, Y. Matsuzawa, 2001, Biochemical and biophysical research communications.

Significance of measuring serum concentrations of remnant lipoproteins and apolipoprotein B-48 in fasting period.

S. Yamashita, F. Hayashi, S. Kawano, 2009, Journal of atherosclerosis and thrombosis.

Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases.

S. Yamashita, I. Komuro, M. Nishida, 2012, Journal of atherosclerosis and thrombosis.

patient-oriented and epidemiological research Chylomicron remnants are increased in the postprandial state in CD36 deficiency

S. Yamashita, I. Shimomura, M. Hori, 2009 .

Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells.

S. Kihara, S. Yamashita, T. Funahashi, 1998, Atherosclerosis.

Profile Rationale and Design of the PROSPECTIVE Trial : Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease

S. Yamashita, Y. Matsuzawa, M. Matsuzaki, 2016 .

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Effect of weight loss on markers of triglyceride‐rich lipoprotein metabolism in the metabolic syndrome

S. Yamashita, G. Watts, T. Ng, 2008, European journal of clinical investigation.

Diagnosis of Atherosclerosis

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Diagnosis of atherosclerosis. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Acetylcholine-Induced Coronary Microvascular Vasospasm in a Patient with Angina Pectoris and Normal Coronary Angiogram

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1997, Angiology.

Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β-catenin activation.

S. Yamashita, Y. Sakata, M. Nishida, 2019, Journal of molecular and cellular cardiology.

Enhanced expression of rat obese (ob) gene in adipose tissues of ventromedial hypothalamus (VMH)-lesioned rats.

S. Yamashita, T. Funahashi, I. Shimomura, 1995, Biochemical and biophysical research communications.

Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women.

S. Yamashita, Y. Matsuzawa, S. Fujioka, 1996, Hypertension.

Current Diagnosis and Management of Tangier Disease

S. Yamashita, K. Matsuki, K. Tsukamoto, 2021, Journal of atherosclerosis and thrombosis.

Accelerated Atherogenicity in Tangier Disease

S. Yamashita, Y. Matsuzawa, M. Nishida, 2018, Journal of atherosclerosis and thrombosis.

Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions.

K. Matsumoto, S. Yamashita, Y. Matsuzawa, 1999, Circulation research.

Tangier disease with continuous massive and longitudinal diffuse calcification in the coronary arteries : demonstration by the sagittal images of intravascular ultrasonography.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 2000, Circulation.

Dominant expression of ATP-binding cassette transporter-1 on basolateral surface of Caco-2 cells stimulated by LXR/RXR ligands.

S. Yamashita, Y. Matsuzawa, K. Ueda, 2002, Biochemical and biophysical research communications.

Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?

S. Yamashita, G. Watts, I. Martins, 2005, Clinical endocrinology.

Effects of Selective PPARα Modulator K-877 on Particle Numbers of Lipoprotein Subclasses in Dyslipidemic Patients: Analysis by GP-HPLC and NMR Lipoprofile 2 and 3

S. Yamashita, H. Arai, E. Araki, 2018, Atherosclerosis Supplements.

A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters

S. Yamashita, H. Arai, E. Araki, 2018, Atherosclerosis Supplements.

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

G. Francis, Qian Wang, D. Gaudet, 2021, The Lancet.

region : the ' ' Ten Countries Study ' ' primary care physicians in the Asia-Pacific familial hypercholesterolaemia among and preferences concerning the care of questionnaire into knowledge , awareness An enquiry based on a standardised

S. Yamashita, G. Watts, A. Ramli, 2017 .

An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the “Ten Countries Study”

S. Yamashita, G. Watts, A. Ramli, 2017, BMJ Open.

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

S. Yamashita, B. Tomlinson, D. Masuda, 2015, Disease markers.

Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan.

S. Yamashita, T. Okamura, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT

S. Yamashita, Y. Matsuzawa, T. Kita, 2021, Journal of atherosclerosis and thrombosis.

New Horizons for Probucol, an Old, Mysterious Drug

S. Yamashita, Y. Matsuzawa, D. Masuda, 2020, Journal of atherosclerosis and thrombosis.

Importance of Early Diagnosis and Treatment of Familial Hypercholesterolemia in Health Examination: Messages from the Japan Atherosclerosis Society

S. Yamashita, 2017 .

Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.

S. Yamashita, I. Komuro, M. Nishida, 2012, Journal of atherosclerosis and thrombosis.

Probucol Enhances the Expression of Human Hepatic Scavenger Receptor Class B Type I, Possibly Through a Species-Specific Mechanism

S. Yamashita, I. Shimomura, T. Maruyama, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.

T Nakamura, S. Kihara, S. Yamashita, 1999, Circulation.

Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography.

S. Yamashita, I. Komuro, Y. Monden, 2012, Metabolism: clinical and experimental.

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease

S. Yamashita, D. Masuda, 2021, Journal of atherosclerosis and thrombosis.

Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesteryl ester transfer protein deficiency

S. Yamashita, Y. Sakata, M. Nishida, 2018, PloS one.

Low HDL/High HDL Syndromes

S. Yamashita, Y. Matsuzawa, N. Sakai, 2004 .

Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia DOI 10.1194/jlr.M100349-JLR200

S. Yamashita, Y. Matsuzawa, M. Nagano, 2002, Journal of Lipid Research.

Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report.

S. Yamashita, Y. Matsuzawa, S. Tarui, 1984, Atherosclerosis.

A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects.

S. Yamashita, Y. Matsuzawa, M. Yamane, 1996, Journal of lipid research.

Molecular Defect and Atherogenicity in Cholesteryl Ester Transfer Protein Deficiency

S. Yamashita, Y. Matsuzawa, T. Arai, 1994, Annals of the New York Academy of Sciences.

A 31-year-old woman with homozygous familial hypercholesterolemia without significant lesions in the coronary arteries.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1986, Atherosclerosis.

Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity.

S. Yamashita, Y. Matsuzawa, S. Tarui, 1988, Atherosclerosis.

Very High Density Lipoproteins Induced by Plasma Cholesteryl Ester Transfer Protein (CETP) Have a Potent Antiatherogenic Function a

S. Yamashita, Y. Matsuzawa, T. Arai, 1994, Annals of the New York Academy of Sciences.

Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.

S. Yamashita, Y. Matsuzawa, D. Sprecher, 1990, The Journal of clinical investigation.

High‐density lipoproteins from probucol‐treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low‐density lipoproteins

S. Yamashita, Y. Matsuzawa, T. Arai, 1997, European journal of clinical investigation.

Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects.

S. Yamashita, M. Menju, T. Arai, 1995, Atherosclerosis.

Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population--relation between the mutation and hyperalphalipoproteinemia.

S. Yamashita, T. Funahashi, M. Menju, 1993, Atherosclerosis.

Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins.

S. Yamashita, Y. Matsuzawa, T. Arai, 1994, Journal of biochemistry.

Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients

S. Yamashita, M. Ishigami, N. Sakai, 2007, Molecular and Cellular Biochemistry.

Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients.

K. Matsumoto, S. Yamashita, Y. Matsuzawa, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

S. Yamashita, Y. Tomiyama, M. Ishigami, 1995, The Journal of clinical investigation.

Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism.

S. Yamashita, I. Komuro, M. Nishida, 2012, Clinica chimica acta; international journal of clinical chemistry.

Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency.

M. Hayden, S. Yamashita, Y. Matsuzawa, 2002, Biochemical and biophysical research communications.

Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism.

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2003, Diabetes care.

Development of a homogeneous assay to measure remnant lipoprotein cholesterol.

S. Yamashita, T. Irie, M. Ishigami, 2007, Clinical chemistry.

Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1996, European Journal of Clinical Pharmacology.

Familial hypercholesterolaemia‐like syndrome with apolipoprotein E‐7 associated with marked Achilles tendon xanthomas and coronary artery disease: a report of two cases

S. Yamashita, Y. Matsuzawa, N. Sakai, 1994, Journal of internal medicine.

Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein

S. Yamashita, Y. Sakata, M. Nishida, 2020, Journal of atherosclerosis and thrombosis.

Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects DOI 10.1194/jlr.M200024-JLR200

S. Yamashita, Y. Matsuzawa, M. Nagano, 2002, Journal of Lipid Research.

Point Mutation (−69 G→A) in the Promoter Region of Cholesteryl Ester Transfer Protein Gene in Japanese Hyperalphalipoproteinemic Subjects

S. Yamashita, Y. Matsuzawa, M. Nagano, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport.

S. Yamashita, Y. Matsuzawa, M. Nishida, 2001, Atherosclerosis.

Impairment of Reverse Cholesterol Transport System and Atherosclerosis

S. Yamashita, Y. Matsuzawa, T. Maruyama, 2000 .

Remnant lipoprotein-cholesterol is a predictive biomarker for large artery atherosclerosis in apparently healthy women: usefulness as a parameter for annual health examinations

S. Yamashita, M. Nishida, T. Moriyama, 2011, Annals of clinical biochemistry.

Genomic structure and mutations in adipose-specific gene, adiponectin

S. Kihara, S. Yamashita, T. Funahashi, 2000, International Journal of Obesity.

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan.

S. Yamashita, Y. Matsuzawa, T. Kita, 2004, Journal of atherosclerosis and thrombosis.

Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader ® assay

S. Yamashita, M. Nagano, T. Egashira, 2002 .

Interferon α induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C

S. Kihara, S. Yamashita, Y. Matsuzawa, 1997, Hepatology.

Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations.

S. Yamashita, I. Shimomura, N. Sakane, 2009, Journal of atherosclerosis and thrombosis.

Molecular genetics of plasma cholesteryl ester transfer protein.

S. Yamashita, Y. Matsuzawa, T. Arai, 1997, Current opinion in lipidology.

Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages.

S. Kihara, S. Yamashita, I. Shimomura, 2008, Biochemical and biophysical research communications.

Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition.

S. Yamashita, Y. Matsuzawa, D. Sprecher, 1991, Metabolism: clinical and experimental.

Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Progranulin plays crucial roles in preserving bone mass by inhibiting TNF-α-induced osteoclastogenesis and promoting osteoblastic differentiation in mice.

S. Yamashita, H. Yoshikawa, T. Noguchi, 2015, Biochemical and biophysical research communications.

Correction: fasting remnant lipoproteins can predict postprandial hyperlipidemia

S. Yamashita, S. Kawano, Y. Fujioka, 2014, Lipids in Health and Disease.

Correlation of fasting serum apolipoprotein B‐48 with coronary artery disease prevalence

S. Yamashita, I. Komuro, M. Nishida, 2012, European journal of clinical investigation.

[Clinical significance of apolipoprotein B-48 (apoB-48) in chronic kidney disease patients].

S. Yamashita, D. Masuda, Y. Hidaka, 2010, Rinsho byori. The Japanese journal of clinical pathology.

Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention.

S. Yamashita, I. Komuro, M. Nishida, 2012, Journal of atherosclerosis and thrombosis.

Mutations in Japanese subjects with primary hyperlipidemia--results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996--.

S. Yamashita, Y. Matsuzawa, T. Kita, 2004, Journal of atherosclerosis and thrombosis.

Adiponectin deficiency suppresses ABCA1 expression and ApoA‐I synthesis in the liver

S. Kihara, S. Yamashita, I. Shimomura, 2007 .

CD36, but not GPR120, is required for efficient fatty acid utilization during endurance exercise

S. Yamashita, S. Matsumura, Kazuo Inoue, 2014, Bioscience, biotechnology, and biochemistry.

Visceral fat accumulation and vascular complications associated with VMH lesioning of spontaneously non-insulin-dependent diabetic GK rat.

S. Yamashita, Y. Matsuzawa, I. Shimomura, 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond.

S. Yamashita, G. Watts, M. Hagger, 2016, Journal of atherosclerosis and thrombosis.

Erratum: Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan [Journal of Atherosclerosis and Thrombosis 1506 292-303]

S. Yamashita, Y. Matsuzawa, T. Kita, 2009 .

Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance.

S. Kihara, S. Yamashita, T. Funahashi, 1997, Atherosclerosis.

Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance.

T Nakamura, H Nishizawa, S. Yamashita, 2001, Diabetes care.

Pharmacokinetics and metabolism of 123I-BMIPP fatty acid analog in healthy and CD36-deficient subjects.

S. Yamashita, Y. Matsuzawa, K. Yamasaki, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A Case of Homozygous:Familial Hypercholesterolemia Presenting Marked Reduction of Serum Cholesterol Following Treatment with CS-514 (Inhibitor of HMG-CoA Reductase) and Posttransfusion Hepatitis

S. Kihara, S. Yamashita, T. Funahashi, 2011 .

Significance of cardiac catheterization for asymptomatic patients with familial hypercholesterolemia

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1987 .

Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia--a possible pathogenesis of necrobiotic xanthogranuloma.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1999, Atherosclerosis.

Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1998, Metabolism: clinical and experimental.

Anti-GPIHBP1 Antibody-Positive Autoimmune Hyperchylomicronemia and Immune Thrombocytopenia

S. Yamashita, Y. Sakata, M. Nishida, 2022, Journal of atherosclerosis and thrombosis.

Autoimmune hyperchylomicronemia.

S. Kihara, S. Yamashita, T. Funahashi, 1989, The New England journal of medicine.

Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1992, Atherosclerosis.

Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia.

S. Yamashita, I. Komuro, M. Nishida, 2011, Journal of atherosclerosis and thrombosis.

Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway

S. Kihara, S. Yamashita, T. Funahashi, 2000, Circulation.

Methods for Studying the Function of Progranulin in Atherosclerosis Using Both Knockout Mice Models and In Vitro Studies.

S. Yamashita, Y. Sakata, T. Ohama, 2018, Methods in molecular biology.

Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice.

S. Yamashita, I. Komuro, M. Nishida, 2013, Cardiovascular research.

Relationship between LDL receptor activity and development of coronary heart disease in Japanese cases with heterozygous familial hypercholesterolemia.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1987, Artery.

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

T Nakamura, S. Kihara, S. Yamashita, 1999, Biochemical and biophysical research communications.

Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals.

S. Yamashita, M. Nishida, N. Tada, 2014, Journal of atherosclerosis and thrombosis.

Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia

S. Yamashita, M. Nishida, M. Ishigami, 2009, European journal of clinical investigation.

Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2003, Atherosclerosis.

[Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease].

S. Yamashita, T. Ohama, D. Masuda, 2009, Rinsho byori. The Japanese journal of clinical pathology.

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

S. Yamashita, H. Maegawa, J. Satoh, 2019, Diabetes, obesity & metabolism.

The lipoprotein fraction between VLDL and LDL detected by biphasic agarose gel electrophoresis reflects serum remnant lipoprotein and Lp(a) concentrations.

S. Yamashita, F. Hayashi, S. Kawano, 2006, Journal of atherosclerosis and thrombosis.

Localization of CD36 and scavenger receptor class A in human coronary arteries--a possible difference in the contribution of both receptors to plaque formation.

S. Yamashita, Y. Matsuzawa, M. Nishida, 2001, Atherosclerosis.

Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

M. Matsuda, S. Yamashita, I. Shimomura, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Marked hyperalphalipoproteinemia is not a longevity syndrome. Insights from a cohort study in a city where CETP deficiency accumulates

S. Yamashita, Y. Matsuzawa, T. Arai, 1994 .

Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases

S. Yamashita, 2018, Health Evaluation and Promotion.

Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages.

K. Matsumoto, S. Yamashita, T. Funahashi, 1998, Arteriosclerosis, thrombosis, and vascular biology.

CD36 deficiency and insulin resistance

S. Yamashita, Y. Matsuzawa, K. Hirano, 2001, The Lancet.

CD36 mediates long-chain fatty acid transport in human myocardium: Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency

S. Yamashita, Y. Matsuzawa, Y. Tomiyama, 1999, Molecular and Cellular Biochemistry.

Plasma cholesteryl ester transfer protein (CETP) induces very high density lipoproteins (VHDL) with a potent anti-atherogenic function

S. Yamashita, Y. Matsuzawa, T. Arai, 1994 .

The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease.

T Nakamura, H Nishizawa, S. Kihara, 2001, Obesity research.

Rapid enhancement of acyl-CoA synthetase, LPL, and GLUT-4 mRNAs in adipose tissue of VMH rats.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1996, The American journal of physiology.

Increased prop ion of plasma apoB-48 to apoB-100 in non-insulin-dependent diabetic rats : contribution of enhanced apoB mRNA e liver ng in the

S. Kihara, S. Yamashita, I. Shimomura, 2002 .

Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes

S. Yamashita, Y. Matsuzawa, H. Arai, 2019, Journal of atherosclerosis and thrombosis.

Hypocholesterolaemic factor from gallbladder cancer cells

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1990, The Lancet.

A novel molecular basis for genetic cholesteryl ester transfer protein (CETP) deficiency — G to A mutation in consensus ETS binding site at the promoter region of CETP gene

S. Yamashita, Y. Matsuzawa, M. Nagano, 2000 .

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis

S. Yamashita, D. Masuda, 2017, Journal of atherosclerosis and thrombosis.

Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.

S. Kihara, S. Yamashita, T. Funahashi, 1998, Atherosclerosis.

Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity.

S. Yamashita, Y. Matsuzawa, M. Yamane, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects.

P. Duchateau, S. Yamashita, Y. Matsuzawa, 2000, Journal of lipid research.

A delayed-addition enzyme immunoassay for the relative cholesteryl ester transfer protein mass in patients with deficient plasma cholesteryl ester transfer activity.

S. Yamashita, Y. Matsuzawa, D. Sprecher, 1990, Clinica chimica acta; international journal of clinical chemistry.

Evaluation of a homogeneous assay for measuring LDL-cholesterol in hyperlipidemic serum specimens.

S. Yamashita, I. Shimomura, M. Nishida, 2008, Journal of atherosclerosis and thrombosis.

CHARACTERISTICS OF CORONARY HEART DISEASE (CHD) IN FIMILIAL HYPERCHOLESTEROLEMIA (FH) AND ITS INCIDENCE IN FH WITHOUT CLINICAL CARDIAC SYMPTOM : Atherosclerosis : PROCEEDINGS OF THE 50th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1986 .

Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages

S. Kihara, S. Yamashita, T. Funahashi, 2001, Circulation.

Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction

S. Yamashita, Y. Sakata, M. Nishida, 2019, Journal of atherosclerosis and thrombosis.

Interferon Alpha Induces Disorder of Lipid Metabolism by Lowering Postheparin Lipases and Cholesteryl Ester Transfer Protein Activities in Patients With Chronic Hepatitis C

S. Kihara, S. Yamashita, T. Arai, 1998 .

Bis(Monoacylglycero)Phosphate Accumulation in Macrophages Induces Intracellular Cholesterol Redistribution, Attenuates Liver-X Receptor/ATP-Binding Cassette Transporter A1/ATP-Binding Cassette Transporter G1 Pathway, and Impairs Cholesterol Efflux

S. Yamashita, M. Lagarde, E. Lefai, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Pressure Overload Impairs Cardiac Function in Long-Chain Fatty Acid Transporter CD36-Knockout Mice.

S. Yamashita, I. Komuro, Y. Sakata, 2019, International heart journal.

Marked hypocholesterolemia in a case with adrenal adenoma--enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells.

S. Yamashita, T. Funahashi, M. Menju, 1995, The Journal of clinical endocrinology and metabolism.

A 31-Year-Old Woman with Homozygous Hypercholesterolemia without Significant in the Coronary Arteries Familial Lesions

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1986 .

An atypical case of abetalipoproteinaemia with severe fatty liver in the absence of steatorrhoea or acanthocytosis

S. Yamashita, M. Nagano, T. Egashira, 2005, European Journal of Pediatrics.

Receptor Pathway and Enhanced by Hypoxic Conditions Lipid Accumulation in Smooth Muscle Cells Under LDL Loading Is Independent of LDL

S. Yamashita, Y. Matsuzawa, T. Kodama, 2013 .

Lipid Accumulation in Smooth Muscle Cells Under LDL Loading Is Independent of LDL Receptor Pathway and Enhanced by Hypoxic Conditions

S. Yamashita, Y. Matsuzawa, T. Kodama, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction

S. Yamashita, M. Nishino, Hiroyasu Kato, 2022, ESC Heart Failure.

The Role of Microsomal Triglyceride Transfer Protein (MTP) in the Mechanism of Hyperlipidemia Under Overnutrition State

S. Yamashita, T. Funahashi, M. Ishigami, 2011 .

Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver.

S. Kihara, S. Yamashita, I. Shimomura, 2008, FEBS letters.

Familial hypercholesterolemia.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.

S. Yamashita, T. Hayakawa, A. Matsuyama, 2011, Biochemical and biophysical research communications.

Transplantation of human adipose tissue-derived multilineage progenitor cells reduces serum cholesterol in hyperlipidemic Watanabe rabbits.

S. Yamashita, T. Hayakawa, A. Matsuyama, 2011, Tissue engineering. Part C, Methods.

Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction

S. Yamashita, M. Nishino, Hiroyasu Kato, 2022, ESC Heart Failure.

Considerable scatter in the relationship between left atrial volume and pressure in heart failure with preserved left ventricular ejection fraction

S. Yamashita, M. Nishino, Hiroyasu Kato, 2020, Scientific Reports.

A compound heterozygote for familial hypercholesterolaemia with a homozygous mother

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1996, Journal of internal medicine.

RECS1 is a negative regulator of matrix metalloproteinase-9 production and aged RECS1 knockout mice are prone to aortic dilation.

S. Yamashita, Y. Matsuzawa, H. Nojima, 2006, Circulation journal : official journal of the Japanese Circulation Society.

RECS1 deficiency in mice induces susceptibility to cystic medial degeneration.

S. Yamashita, Y. Matsuzawa, M. Ikawa, 2006, Genes & genetic systems.

[HDL and arteriosclerosis].

S. Yamashita, Y. Matsuzawa, 1992, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Genetic analysis of a Japanese cerebrotendinous xanthomatosis family: identification of a novel mutation in the adrenodoxin binding region of the CYP 27 gene.

S. Yamashita, Y. Matsuzawa, M. Menju, 1996, Biochimica et biophysica acta.

Senescent phenotypes of skin fibroblasts from patients with Tangier disease.

S. Yamashita, I. Shimomura, M. Hori, 2007, Biochemical and biophysical research communications.

Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model

S. Yamashita, I. Komuro, M. Nishida, 2017, Scientific Reports.

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia

S. Yamashita, T. Okamura, H. Arai, 2020, Journal of atherosclerosis and thrombosis.

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report

S. Yamashita, D. Masuda, M. Koseki, 2020, Cardiovascular Diabetology.

2. Evidence of Lipid Intervention in Japanese

S. Yamashita, 2009 .

High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans.

S. Yamashita, Y. Matsuzawa, T. Kawasaki, 1995, Atherosclerosis.

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin

S. Yamashita, D. Masuda, Daisaku Masuda, 2020, Journal of atherosclerosis and thrombosis.

Long-Term Treatment With Evolocumab Among Japanese Patients　- Final Report of the OSLER Open-Label Extension Studies.

S. Yamashita, A. Hirayama, A. Kiyosue, 2019, Circulation journal : official journal of the Japanese Circulation Society.

Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism.

S. Yamashita, M. Nishida, T. Ohama, 2010, Journal of atherosclerosis and thrombosis.

Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects

S. Kihara, S. Yamashita, Y. Matsuzawa, 1997, Journal of internal medicine.

Acute ST-segment elevation myocardial infarction is associated with decreased human antimicrobial peptide LL-37 and increased human neutrophil peptide-1 to 3 in plasma.

S. Yamashita, Li Song, Hongbing Yan, 2012, Journal of atherosclerosis and thrombosis.

Immunohistochemical localization of fatty acid transporters and MCT1 in the sebaceous glands of mouse skin.

T. Iwanaga, S. Yamashita, Kazuo Inoue, 2016, Biomedical research.

Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention

S. Yamashita, M. Rizzo, T. Su, 2022, Metabolites.

Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

M. Matsuda, M. Nishizawa, K. Segawa, 2005, Science.

Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis.

S. Yamashita, T. Suda, M. Tabata, 2009, Biochemical and biophysical research communications.

Statement for Appropriate Clinical Use of PCSK9 Inhibitors

S. Yamashita, K. Kitagawa, K. Tsukamoto, 2018, Journal of atherosclerosis and thrombosis.

Lipids / Lipoproteins Wednesday , August 2 , 9 : 30 am – 5 : 00 pm B-139 Multicenter Evaluation of new HDL-Cholesterol Generation 4 assay ( HDLC 4 ) on Roche Clinical Chemistry Analyzers

I.., S. Yamashita, Y. Sakata, 2017 .

Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency).

S. Yamashita, Y. Matsuzawa, K. Fukuchi, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.

S. Yamashita, G. Watts, E. Sijbrands, 2014, International journal of cardiology.

Myocardial energy provision is preserved by increased utilization of glucose and ketone bodies in CD36 knockout mice.

S. Yamashita, T. Watabe, M. Imaizumi, 2015, Metabolism: clinical and experimental.

Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E Suita).

S. Kihara, S. Yamashita, T. Funahashi, 1997, Atherosclerosis.

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

S. Kihara, S. Yamashita, T. Funahashi, 2001, Diabetes research and clinical practice.

Long-Term Treatment With Evolocumab Among Japanese Patients ― Final Report of the OSLER Open-Label Extension Studies ― LATE BREAKING CLINICAL TRIAL (JCS 2019)

S. Yamashita, Andrew Hamer, A. Kiyosue, 2019 .

Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults.

S. Yamashita, J. Sasaki, N. Yamada, 2002, Journal of atherosclerosis and thrombosis.

Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma.

S. Yamashita, Y. Matsuzawa, S. Nozaki, 1997, Internal medicine.

CD 36 mediates long-chain fatty acid transport in human myocardium : Complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD 36 deficiency

Tsutomu, S. Yamashita, Y. Matsuzawa, 2022 .

Pros and cons of inhibiting cholesteryl ester transfer protein

S. Yamashita, Y. Matsuzawa, K. Hirano, 2000, Current opinion in lipidology.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.

S. Yamashita, H. Arai, E. Araki, 2017, Journal of clinical lipidology.

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

F. Hu, R. Ross, J. Després, 2020, Nature Reviews Endocrinology.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

P. Libby, P. Ridker, J. Després, 2019, Cardiovascular Diabetology.

Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1β Release from Murine Peritoneal Macrophages: Role of CD361

S. Yamashita, Y. Ikeda, A. Murakami, 2007, The Journal of Immunology.

Ectopic expression of alpha1,6 fucosyltransferase in mice causes steatosis in the liver and kidney accompanied by a modification of lysosomal acid lipase.

S. Yamashita, Y. Matsuzawa, Y. Ikeda, 2001, Glycobiology.

Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.

S. Yamashita, Y. Matsuzawa, M. Matsuzaki, 2016, Journal of atherosclerosis and thrombosis.

Aquaporin Adipose, a Putative Glycerol Channel in Adipocytes*

M. Matsuda, S. Kihara, S. Yamashita, 2000, The Journal of Biological Chemistry.

C-Terminal Tails of Sulfonylurea Receptors Control ADP-Induced Activation and Diazoxide Modulation of ATP-Sensitive K+ Channels

S. Yamashita, Y. Matsuzawa, Y. Kurachi, 2000, Circulation research.

Establishment of a Novel Murine Model of Ischemic Cardiomyopathy with Multiple Diffuse Coronary Lesions

S. Yamashita, I. Komuro, M. Nishida, 2013, PloS one.

Statin Intolerance Clinical Guide 2018

S. Yamashita, T. Nakayama, H. Saito, 2020, Journal of atherosclerosis and thrombosis.

Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.

S. Yamashita, Y. Matsuzawa, C. Sirtori, 2018, Atherosclerosis.

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

S. Yamashita, G. Watts, S. Gidding, 2020, Nature Reviews Cardiology.

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

S. Yamashita, G. Watts, E. Sijbrands, 2015, European journal of preventive cardiology.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation.

S. Yamashita, G. Watts, E. Sijbrands, 2014, Journal of clinical lipidology.

Recent advances in synthetic pharmacotherapies for dyslipidaemias

S. Yamashita, G. Watts, C. Sirtori, 2019, European journal of preventive cardiology.

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

S. Kihara, S. Yamashita, T. Hiro, 2018, Journal of atherosclerosis and thrombosis.

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

S. Yamashita, H. Arai, T. Teramoto, 2018, Journal of atherosclerosis and thrombosis.

EFFECTS OF PROBUCOL ON LIPOPROTEIN CONCENTRATIONS AND LDL OXIDATION

S. Yamashita, Y. Matsuzawa, D. Masuda, 2015 .

Pulmonary hypertension associated with bone marrow transplantation.

S. Yamashita, I. Komuro, Y. Sakata, 2010, Journal of cardiology cases.

Impaired efflux of cholesterol from aged cells and its molecular mechanism: A basis for age‐related enhancement of atherosclerosis

S. Yamashita, I. Shimomura, M. Nishida, 2007 .

Retarded Intracellular Lipid Transport Associated With Reduced Expression of Cdc42, a Member of Rho-GTPases, in Human Aged Skin Fibroblasts: A Possible Function of Cdc42 in Mediating Intracellular Lipid Transport

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Evaluation of an HPLC method for LDL-cholesterol determination in patients with various lipoprotein abnormalities in comparison with beta-quantification.

S. Yamashita, Masakazu Nakamura, M. Okazaki, 2008, Clinica chimica acta; international journal of clinical chemistry.

Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.

S. Yamashita, H. Arai, T. Teramoto, 2016, Atherosclerosis.

Lipoprotein metabolism and molecular pathogenesis of atherosclerosis

S. Yamashita, Y. Matsuzawa, M. Nishida, 2002 .

CD36 deficiency associated with insulin resistance

S. Yamashita, Y. Matsuzawa, K. Hirano, 2001, The Lancet.

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.

F. Hu, R. Ross, J. Després, 2019, The lancet. Diabetes & endocrinology.

Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis.

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1996, Circulation.

Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques.

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1995, The Journal of clinical investigation.

Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection.

S. Yamashita, Y. Matsuzawa, H. Brewer, 1996, Journal of lipid research.

Did we abandon probucol too soon?

S. Yamashita, Y. Matsuzawa, D. Masuda, 2015, Current opinion in lipidology.

XCR1+ conventional dendritic cell-induced CD4+ T helper 1 cell activation exacerbates cardiac remodeling after ischemic myocardial injury.

S. Yamashita, E. Morii, M. Nishida, 2023, Journal of molecular and cellular cardiology.

Familial massive tendon xanthomatosis with decreased high-density lipoprotein-mediated cholesterol efflux.

S. Yamashita, M. Nishida, N. Sakai, 2005, Metabolism: clinical and experimental.

CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta.

K. Matsumoto, S. Yamashita, Y. Matsuzawa, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

S. Yamashita, H. Arai, E. Araki, 2021, Journal of atherosclerosis and thrombosis.

Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells.

S. Kihara, S. Yamashita, Y. Matsuzawa, 1998, Circulation.

An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls

T Nakamura, S. Kihara, S. Yamashita, 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid Chromatography

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.

S. Yamashita, Y. Matsuzawa, N. Sakai, 2000, Biochimica et biophysica acta.

Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation

S. Yamashita, Y. Matsuzawa, 2016, Current opinion in lipidology.

Lipoprotein Subfractions Highly Associated With Renal Damage in Familial Lecithin: Cholesterol Acyltransferase Deficiency

S. Yamashita, Y. Aoyagi, E. Stroes, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Diagnostic criteria for dyslipidemia.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023, Journal of atherosclerosis and thrombosis.

Serum Values of Cholesterol Absorption and Synthesis Biomarkers in Japanese Healthy Subjects: The CACHE Study HEALTHY Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023, Journal of atherosclerosis and thrombosis.

Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese.

S. Yamashita, Y. Matsuzawa, M. Nagano, 2004, Journal of atherosclerosis and thrombosis.

Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)

S. Yamashita, Y. Matsuzawa, M. Matsuzaki, 2020, Journal of atherosclerosis and thrombosis.

Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency.

S. Yamashita, Y. Sakata, M. Nishida, 2019, Journal of clinical lipidology.

Chapter 1 – Molecular Mechanisms of Hyperalphalipoproteinemia

S. Yamashita, T. Ohama, D. Masuda, 2017 .

Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia

S. Yamashita, B. Tomlinson, V. Lee, 2015, Medicine.

Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

The elderly.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Combination of Neutrophil‐to‐Lymphocyte and Platelet‐to‐Lymphocyte Ratios as a Novel Predictor of Cardiac Death in Patients With Acute Decompensated Heart Failure With Preserved Left Ventricular Ejection Fraction: A Multicenter Study

S. Yamashita, R. Shutta, S. Hikoso, 2022, Journal of the American Heart Association.

Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice

T. Saibara, S. Yamashita, Y. Sakata, 2021, Frontiers in Endocrinology.

Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus.

S. Yamashita, H. Tamura, S. Ishii, 2008, Diabetes research and clinical practice.

Comprehensive risk management for the prevention of cerebro- cardiovascular diseases in Japan

S. Yamashita, H. Iso, H. Shiomi, 2017, Hypertension Research.

Considerable scatter in the relationship between left atrial volume and pressure in heart failure with preserved left ventricular ejection fraction

S. Yamashita, M. Nishino, Hiroyasu Kato, 2020, Scientific Reports.

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State

S. Yamashita, S. Yokoyama, T. Miida, 2017, Journal of atherosclerosis and thrombosis.

Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients

W. Chu, S. Yamashita, Defeng Wang, 2012, Journal of Lipid Research.

Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022

S. Yamashita, K. Matsuki, H. Tada, 2023, Journal of atherosclerosis and thrombosis.

Guidance for Pediatric Familial Hypercholesterolemia 2017

S. Yamashita, K. Yokote, A. Nohara, 2018, Journal of atherosclerosis and thrombosis.

Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.

S. Yamashita, D. Masuda, Yuko Miyata, 2019, Atherosclerosis.

Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intolerance.

S. Yamashita, Y. Matsuzawa, T. Maruyama, 2001, The Journal of clinical investigation.

Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver.

S. Kihara, S. Yamashita, I. Shimomura, 2007, Biochemical and biophysical research communications.

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

S. Yamashita, H. Arai, E. Araki, 2017, Atherosclerosis.

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

S. Yamashita, T. Kodama, H. Arai, 2016, Atherosclerosis.

Evaluation of the efficacy of LAMP-based SARS-CoV-2 detection with simple RNA extraction from nasopharyngeal swabs: A prospective observational study

S. Yamashita, C. Yamada, Shingo Adachi, 2021, PloS one.

The role ofCD36 in atherogenesis as a receptor for OxLDL

S. Yamashita, Y. Matsuzawa, S. Nozaki, 2000 .

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

S. Yamashita, H. Arai, K. Kajinami, 2019, Journal of atherosclerosis and thrombosis.

Defective cholesterol efflux in Werner syndrome fibroblasts and its phenotypic correction by Cdc42, a RhoGTPase

S. Yamashita, I. Shimomura, K. Saijo, 2005, Experimental Gerontology.

Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency

S. Yamashita, T. Funahashi, Y. Matsuzawa, 1995, European journal of clinical investigation.

Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease – the small G protein may play a role in cholesterol efflux

S. Yamashita, T. Suehiro, K. Hirano, 2000, FEBS letters.

Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.

S. Yamashita, Y. Matsuzawa, T. Kita, 2008, Journal of atherosclerosis and thrombosis.

Low HDL and High HDL Syndromes

S. Yamashita, Y. Matsuzawa, 2014 .

Treatment B) Drug Therapy

S. Kihara, S. Yamashita, T. Hiro, 2013 .

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis

Daniel J. Rader, Masahiro Koseki, D. Rader, 2016, Nature.

Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

S. Yamashita, A. Hirayama, T. Teramoto, 2014, Circulation journal : official journal of the Japanese Circulation Society.

Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels.

S. Yamashita, I. Komuro, Y. Monden, 2011, Atherosclerosis.

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice

S. Yamashita, Y. Sakata, M. Nishida, 2017, Journal of atherosclerosis and thrombosis.

Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis

M. Takahashi, S. Kihara, S. Yamashita, 2003, European journal of clinical investigation.

Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model

S. Yamashita, I. Komuro, M. Nishida, 2017, Scientific Reports.

Background to discuss guidelines for control of plasma HDL-cholesterol in Japan.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

A Dietary Oxysterol, 7-Ketocholesterol, Exacerbates Imiquimod-Induced Psoriasis-like Dermatitis in Steatohepatitic Mice

T. Saibara, S. Yamashita, S. Hikoso, 2022, International journal of molecular sciences.

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial.

Y. Ouchi, S. Yamashita, Y. Ohashi, 2019, Circulation.

Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis.

K. Matsumoto, S. Yamashita, Y. Matsuzawa, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy

T. Saibara, S. Yamashita, Y. Sakata, 2022, Scientific Reports.

Immunohistochemical localization of Betacellulin, a member of epidermal growth factor family, in atherosclerotic plaques of human aorta.

S. Kihara, S. Yamashita, Y. Matsuzawa, 2001, Atherosclerosis.

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

S. Yamashita, H. Maegawa, J. Satoh, 2018, Diabetes Care.

Comparison of visibility and diagnostic capability of noninvasive coronary angiography by eight-slice multidetector-row computed tomography versus conventional coronary angiography.

Kouichi Yamasaki, S. Yamashita, T. Maruyama, 2004, The American journal of cardiology.

Association of lifestyle-related factors with circadian onset patterns of acute myocardial infarction: a prospective observational study in Japan

S. Yamashita, I. Komuro, M. Hori, 2014, BMJ Open.

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

S. Yamashita, M. Rizzo, T. Su, 2023, Metabolites.

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

S. Yamashita, H. Arai, E. Araki, 2021, Cardiovascular Diabetology.

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

S. Yamashita, H. Arai, E. Araki, 2018, Journal of atherosclerosis and thrombosis.

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　- A Pooled Analysis From the Open-Label Extension OSLER Studies.

S. Yamashita, A. Hirayama, A. Kiyosue, 2017, Circulation journal : official journal of the Japanese Circulation Society.

A role of CD36 in the perception of an oxidised phospholipid species in mice.

S. Yamashita, Kazuhiro Sakamoto, S. Matsumura, 2015, Biomedical research.

Large scale isolation of non-uniform shear stress-responsive genes from cultured human endothelial cells through the preparation of a subtracted cDNA library.

A. Kawabata, S. Yamashita, Y. Matsuzawa, 2002, Atherosclerosis.

Effects of A Novel Acat Inhibitor, F-1394, on the Progression and Regression of Atherosclerotic Lesions in the Aorta of Cholesterol-Fed Rabbits

S. Yamashita, Y. Matsuzawa, A. Islam, 1996 .

Diagnosis and Management of Sitosterolemia 2021

S. Yamashita, K. Matsuki, K. Tsukamoto, 2021, Journal of atherosclerosis and thrombosis.

Comparison of eight- versus 16-slice multidetector-row computed tomography for visibility and image quality of coronary segments.

S. Yamashita, T. Maruyama, I. Konishi, 2004, The American journal of cardiology.

Coronary artery bypass grafting for a patient with Tangier disease.

S. Yamashita, N. Awata, H. Takami, 2002, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.

S. Yamashita, Y. Matsuzawa, M. Yamane, 2003, Atherosclerosis.

Localization of CD9, an enhancer protein for proheparin-binding epidermal growth factor-like growth factor, in human atherosclerotic plaques: possible involvement of juxtacrine growth mechanism on smooth muscle cell proliferation.

S. Kihara, S. Yamashita, Y. Matsuzawa, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 2001, Japanese circulation journal.

Pharmacokinetics and Metabolism of 123 I-BMIPPFatty Acid Analog in Healthy and CD 36-Deficient Subjects

S. Yamashita, Y. Matsuzawa, K. Yamasaki, 2006 .

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022

S. Yamashita, K. Matsuki, K. Yokote, 2023, Journal of atherosclerosis and thrombosis.

Increased plasma HB-EGF associated with obesity and coronary artery disease.

M. Matsuda, S. Kihara, S. Yamashita, 2002, Biochemical and biophysical research communications.

Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study

S. Yamashita, J. Sasaki, S. Kono, 2017, Journal of atherosclerosis and thrombosis.

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients

S. Yamashita, Yoshiya Tanaka, D. Masuda, 2017, Journal of diabetes investigation.

Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men.

S. Yamashita, T. Funahashi, Y. Matsuzawa, 2001, Japanese circulation journal.

Cloning and functional expression of a novel isoform of ROMK inwardly rectifying ATP‐dependent K+ channel, ROMK6 (Kir1.1 f)

S. Yamashita, Y. Matsuzawa, Y. Horio, 1996 .

Cloning and functional expression of a novel isoform of ROMK inwardly rectifying ATP-dependent K+ channel, ROMK6 (Kir1.1f).

S. Yamashita, Y. Matsuzawa, Y. Horio, 1996, FEBS letters.

Acute accumulation of free cholesterol induces the degradation of perilipin 2 and Rab18-dependent fusion of ER and lipid droplets in cultured human hepatocytes

S. Yamashita, M. Lagarde, Toshihide Kobayashi, 2016, Molecular biology of the cell.

Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.

S. Yamashita, G. Watts, D. Chan, 2012, Atherosclerosis.

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)

S. Kihara, S. Yamashita, Y. Sakata, 2017, Journal of atherosclerosis and thrombosis.

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Laney K. Jones, P. Libby, S. Yamashita, 2023, Nature Reviews Cardiology.

Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey

P. Libby, S. Yamashita, Y. Matsuzawa, 2020, Lipids in Health and Disease.

Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals

S. Yamashita, T. Okamura, M. Kuzuya, 2020, Journal of atherosclerosis and thrombosis.

Abstract 10718: Efficacy and Safety of K-877, a Potent and Selective PPAR-a Agonist, in Japanese Patients With Dyslipidemia

S. Yamashita, T. Kodama, H. Arai, 2013 .

Abstract 15652: Comparison of the Novel Peroxisome Proliferator-Activated Receptor Alpha Agonist K-877 and Fenofibrate on High-Density Lipoprotein Subclass Distribution Determined by High-Performance Liquid Chromatography in Patients With Dyslipidemia

S. Yamashita, T. Kodama, H. Arai, 2013 .

Adiposity measures and mortality in an Asian population

S. Yamashita, Y. Matsuzawa, 2020, Nature Reviews Endocrinology.

DEVELOPMENT AND CLINICAL APPLICATION OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR OXIDIZED HIGH DENSITY LIPOPROTEIN

S. Yamashita, M. Nishida, T. Ohama, 2020 .

Expression of high-density lipoprotein receptors, scavenger receptor class B type I in human central nervous system

S. Yamashita, Y. Matsuzawa, K. Hirano, 2000 .

Fasting remnant lipoproteins can predict postprandial hyperlipidemia

S. Yamashita, S. Kawano, Y. Fujioka, 2012, Lipids in Health and Disease.

[Microsomal triglyceride transfer protein (MTP)].

S. Yamashita, 2001, Nihon rinsho. Japanese journal of clinical medicine.

Correction: fasting remnant lipoproteins can predict postprandial hyperlipidemia

S. Yamashita, S. Kawano, Y. Fujioka, 2014, Lipids in Health and Disease.

Contribution of visceral fat accumulation to the development of atherosclerosis in non-obese subjects

S. Yamashita, Y. Matsuzawa, I. Shimomura, 1994 .

Relationship between Diabetes Mellitus and Serum Lathosterol and Campesterol Levels: The CACHE Study DM Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2022, Journal of atherosclerosis and thrombosis.

Mutation in Bombesin Receptor Subtype-3 Gene is not a Major Cause of Obesity in the Japanese

S. Yamashita, T. Funahashi, K. Kotani, 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

S. Yamashita, G. Watts, A. Ramli, 2017, BMJ Open.

Absolute risk of cardiovascular disease and lipid management targets.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Relationship between Diabetes Mellitus and Serum Lathosterol and Campesterol Levels: The CACHE Study DM Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023 .

ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP.

S. Yamashita, K. Hirano, T. Ohama, 2001, Biochemical and biophysical research communications.

Risk stratification based on metabolic syndrome as well as non- metabolic risk factors in the assessment of carotid atherosclerosis.

Y. Ouchi, S. Yamashita, H. Iso, 2011, Journal of atherosclerosis and thrombosis.

Insulin resistance and body fat distribution.

S. Yamashita, Y. Matsuzawa, T. Nakamura, 1996, Diabetes care.

Differential reactivities of four homogeneous assays for LDL-cholesterol in serum to intermediate-density lipoproteins and small dense LDL: comparisons with the Friedewald equation.

S. Yamashita, M. Nishida, M. Ishigami, 2009, Clinica chimica acta; international journal of clinical chemistry.

Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias

S. Yamashita, A. Matsuyama, Daisaku Masuda, 2015 .

Expression of CD36 by Olfactory Receptor Cells and Its Abundance on the Epithelial Surface in Mice

T. Iwanaga, S. Yamashita, S. Matsumura, 2015, PloS one.

Title Expression of CD 36 by Olfactory Receptor Cells and ItsAbundance on the Epithelial Surface in Mice

T. Iwanaga, S. Yamashita, S. Matsumura, 2019 .

CD36 involvement in the olfactory perception of oleic aldehyde, an odour-active volatile compound, in mice.

S. Yamashita, Kazuo Inoue, Takahiko Amitsuka, 2017, Biomedical research.

Abdoninal Fat:Standardized Technique for Mesurement at CT

S. Yamashita, T. Funahashi, Y. Matsuzawa, 2004 .

Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.

S. Yamashita, H. Arai, T. Teramoto, 2016, Atherosclerosis.

HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.

S. Yamashita, T. Hayakawa, A. Matsuyama, 2011, Biochemical and biophysical research communications.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Increased proportion of plasma apoB-48 to apoB-100 in non-insulin-dependent diabetic rats: contribution of enhanced apoB mRNA editing in the liver.

S. Kihara, S. Yamashita, I. Shimomura, 1995, Journal of lipid research.

Matrix Metalloproteinases as Novel Disease Markers in Takayasu Arteritis

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2003, Circulation.

Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.

S. Yamashita, T. Ng, D. Chan, 2005, Clinical biochemistry.

Chronic kidney disease.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Recent Advances in Analytical Methods on Lipoprotein Subclasses: Calculation of Particle Numbers from Lipid Levels by Gel Permeation HPLC Using "Spherical Particle Model".

S. Yamashita, M. Okazaki, 2016, Journal of oleo science.

Clinical Characteristics of Homozygous Familial Hypercholesterolemia in Japan

S. Yamashita, K. Matsuki, T. Miida, 2023, JACC. Asia.

Prevalence of low HDL-cholesterol and the metabolic syndrome

S. Yamashita, Y. Matsuzawa, N. Sakai, 2004 .

Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease.

S. Yamashita, I. Komuro, M. Nishida, 2012, Journal of atherosclerosis and thrombosis.

Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice.

S. Yamashita, I. Komuro, M. Nishida, 2013, Cardiovascular research.

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

G. Francis, Qian Wang, D. Gaudet, 2021, Lancet.

M.584 Matrix metalloproteinases as novel disease markers in takayasu arteritis

S. Yamashita, Y. Matsuzawa, M. Ishigami, 2004 .

S. Yamashita, M. Lagarde, E. Lefai, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

S. Yamashita, H. Arai, K. Kajinami, 2019, Journal of atherosclerosis and thrombosis.

Progranulin plays crucial roles in preserving bone mass by inhibiting TNF-α-induced osteoclastogenesis and promoting osteoblastic differentiation in mice.

S. Yamashita, H. Yoshikawa, T. Noguchi, 2015, Biochemical and biophysical research communications.

The elderly.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.